A Study of Safety and Efficacy of DPP-4 inhibitor in the Treatment of type 2 diabetes in Kanagawa

A Study of Safety and Efficacy of DPP-4 inhibitor in the Treatment of type 2 diabetes in Kanagawa - ASSET-K

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014382

Enrollment

860

Registered

2014-06-27

Start date

2014-06-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Type 2 diabetic outpatients 2) Patients treated with Sitagliptin for more than 4-5 years whose blood sugar control is inadequate 3) Patients aged >=20 years

Exclusion criteria

Exclusion criteria: 1) Patients with a history of hypersensitivity to Sitagliptin 2) Patients who have history of diabetic ketoacidosis, or diabetic coma in the past 6 months 3) Patients with serious infectious disease, before operation, serious trauma 4) Patients with severe renal failure

Design outcomes

Primary

Measure	Time frame
Changes of HbA1c	—

Secondary

Measure	Time frame
1)Change of fasting plasma glucose level, body weight, Serum lipids [TC, HDL-C, TG, LDL-C], serum creatinine, office blood pressure,AST,ALT,gamma-GTP,BUN,uric acid,urine protein, 2)adverse events	—

Countries

Japan

Contacts

Public ContactKou Kayukawa

Nouvelle Place Inc R.M.O

asset-k@n-place.co.jp03-3814-1616

Outcome results